comprehensive -WSS

comprehensive

author：fashion 2025-09-30 20:47:35 - browse：16281

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： 'Cuddling' is just what the doctor ordered for a 200

WSS

Rock icon Freddie Mercury pre

Bring on the sabbaticals for nurses

What Kate Middleton's cancer revelation might teach the world

Taylor Swift shares sweet moment with Kobe Bryant's daughter Bianka at Eras Tour concert

Readout Newsletter: Illumina, CRISPR, Regeneron

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Affirmative action in medical school literally saved lives

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Affirmative action in medical school literally saved lives

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

As demand for Covid shots wanes, Moderna seeks its next success

Russian court extends detention of American musician

Hepatitis C has a cure — but many Americans still lack access to it

'Cuddling' is just what the doctor ordered for a 200

FDA approval of Sarepta Duchenne genetic therapy gives me hope

'Cuddling' is just what the doctor ordered for a 200

knowledge

Diabetes management: Digital health tools fall short, study says

Russian court extends detention of American musician

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

CRISPR technology availability, affordability needs to be expanded

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

hotspot

leisure time

leisure time

hotspot